Ultragenyx Pharmaceutical Inc. (RARE) has announced its revenue projection for 2024, anticipating a total between $555 million and $560 million. This forecast surpasses the revised guidance issued in August 2024 and indicates an approximate 29% increase compared to 2023.
The company expects Crysvita's revenue to be in the range of $405 million to $410 million for 2024. This estimate also surpasses previous guidance figures and reflects a growth of roughly 24% over the prior year. Similarly, Dojolvi’s revenue is projected to be between $87 million and $89 million, exceeding projected guidance and indicating a growth of around 25% from 2023.
Looking ahead to 2025, Ultragenyx anticipates total revenue to range from $640 million to $670 million. The company plans to provide detailed guidance on 2025's Crysvita and Dojolvi revenue alongside its financial disclosures for the fourth quarter and full fiscal year 2024 in February 2025.
The material has been provided by InstaForex Company - www.instaforex.com
The company expects Crysvita's revenue to be in the range of $405 million to $410 million for 2024. This estimate also surpasses previous guidance figures and reflects a growth of roughly 24% over the prior year. Similarly, Dojolvi’s revenue is projected to be between $87 million and $89 million, exceeding projected guidance and indicating a growth of around 25% from 2023.
Looking ahead to 2025, Ultragenyx anticipates total revenue to range from $640 million to $670 million. The company plans to provide detailed guidance on 2025's Crysvita and Dojolvi revenue alongside its financial disclosures for the fourth quarter and full fiscal year 2024 in February 2025.
The material has been provided by InstaForex Company - www.instaforex.com